Pediatrix Medical Group, Inc. SEC Filings

MD filed a Form 144 notice covering a planned sale of common stock. The filing states an intent to sell 10,478 common shares, with an aggregate market value of $240,994, on the NYSE, with an approximate sale date of 11/17/2025. The filing reports that these shares were acquired through stock plan activity from the issuer on several dates in 2021 and 2022. It also notes that total shares of the same class outstanding are 85,877,386. The signer represents that they are not aware of any material adverse, nonpublic information about the issuer’s operations.

Pediatrix Medical Group (MD) reported an insider transaction by a Director. On 11/06/2025, the reporting person sold 10,000 shares of common stock (code S) at a weighted average price of $21.65, with individual trade prices ranging from $21.51 to $21.76.

Following the sale, the reporting person beneficially owned 32,232 shares, held directly. The footnote states the seller will provide full trade-by-trade details within the disclosed price range upon request.

MD filed a Form 144 notice for a proposed sale of 10,000 common shares, reflecting an aggregate market value of $216,150. The filing lists Merrill Lynch as broker, with an approximate sale date of 11/06/2025 on the NYSE.

The shares were acquired via stock plan activity from the issuer in two tranches: 1,480 shares on 05/12/2023 and 8,520 shares on 05/11/2024.

Pediatrix Medical Group (MD) reported stronger Q3 results. Net revenue was $492.9 million versus $511.2 million a year ago, reflecting practice dispositions partly offset by growth at ongoing sites. Net income rose to $71.7 million from $19.4 million, and diluted EPS increased to $0.84 from $0.23. Adjusted EBITDA improved to $87.3 million from $60.2 million as operating margin expanded to 13.8%.

Same‑unit net revenue increased 8.0%, driven by better collections, higher patient acuity in neonatology, higher hospital administrative fees, and a slightly favorable payor mix. Transformational and restructuring expenses declined to $6.0 million. Non‑operating results benefited from a $20.9 million net gain on investments in divested businesses.

For the nine months, revenue was $1.42 billion and net income was $131.7 million. Cash and cash equivalents rose to $340.1 million, aided by lower days sales outstanding of 43.1 days. The company acquired women’s and children’s practices for $19.2 million and repurchased 1.2 million shares for $20.9 million under a new $250 million authorization. Debt included $400.0 million of 2030 notes and $201.6 million on the Term A Loan with $450.0 million revolver availability.

Pediatrix Medical Group, Inc. filed an 8‑K announcing it furnished a press release with results for the three and nine months ended September 30, 2025. The information was provided under Item 2.02 and, along with Exhibit 99.1, is furnished and not deemed filed. The company’s common stock trades on the NYSE under the symbol MD.

Pediatrix Medical Group insider transfer disclosure. Thomas McEachin, a director, reported transfers of common stock on August 19 and August 20, 2025. The filings show 54,021 shares were transferred on August 19, 2025, and 625 shares on August 20, 2025, each reported as dispositions at $0. After the transactions the report lists 11,427 shares held directly and 54,646 shares held indirectly by the Thomas A. McEachin Living Trust dated April 17, 2025. The Form 4 was executed by an attorney-in-fact and signed on August 21, 2025. The reporting person and spouse are identified as trustees and beneficiaries of the trust that holds the reported securities.